XML 18 R8.htm IDEA: XBRL DOCUMENT
v3.22.2

Fair Value Measurements | 6 Months Ended
--- | ---
Jun. 30, 2022
Fair Value Measurements |
Fair Value Measurements | (3) Fair Value Measurements ​ The following tables set forth the Company’s financial assets and liabilities subject to fair value measurements: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | As of | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | June 30, 2022 |  | Level 1 |  | Level 2 |  | Level 3
​ | ​ | (In thousands)
Assets: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Money market funds and cash equivalents | ​ | $ | 7,114 | ​ | ​ | — | ​ | $ | 7,114 | ​ | ​ | —
Marketable securities | ​ | ​ | 328,416 | ​ | ​ | — | ​ | ​ | 328,416 | ​ | ​ | —
​ | ​ | $ | 335,530 | ​ | ​ | — | ​ | $ | 335,530 | ​ | ​ | —
Liabilities: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Kolltan acquisition contingent consideration | ​ | $ | — | ​ | ​ | — | ​ | ​ | — | ​ | $ | —
​ | ​ | $ | — | ​ | ​ | — | ​ | ​ | — | ​ | $ | —
​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | As of | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | December 31, 2021 |  | Level 1 |  | Level 2 |  | Level 3
​ | ​ | (In thousands)
Assets: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Money market funds and cash equivalents | ​ | $ | 26,220 | ​ | ​ | — | ​ | $ | 26,220 | ​ | ​ | —
Marketable securities | ​ | ​ | 369,107 | ​ | ​ | — | ​ | ​ | 369,107 | ​ | ​ | —
​ | ​ | $ | 395,327 | ​ | ​ | — | ​ | $ | 395,327 | ​ | ​ | —
Liabilities: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Kolltan acquisition contingent consideration | ​ | $ | 6,862 | ​ | ​ | — | ​ | ​ | — | ​ | $ | 6,862
​ | ​ | $ | 6,862 | ​ | ​ | — | ​ | ​ | — | ​ | $ | 6,862
​ The Company’s financial assets consist mainly of money market funds, cash equivalents and marketable securities and are classified as Level 2 within the valuation hierarchy. The Company values its marketable securities utilizing independent pricing services which normally derive security prices from recently reported trades for identical or similar securities, making adjustments based on significant observable transactions. At each balance sheet date, observable market inputs may include trade information, broker or dealer quotes, bids, offers or a combination of these data sources. ​ The following table reflects the activity for the Company’s contingent consideration liabilities measured at fair value using Level 3 inputs for the six months ended June 30, 2022 (in thousands): ​
​ | ​ | ​ | ​
​ | ​ | Other Liabilities:
​ | ​ | Contingent
​ |  | Consideration
Balance at December 31, 2021 | ​ | $ | 6,862
Fair value adjustments included in operating expenses | ​ |  | (6,862)
Balance at June 30, 2022 | ​ | $ | —
​ The valuation technique used to measure fair value of the Company’s Level 3 liabilities, which consist of contingent consideration related to the acquisition of Kolltan Pharmaceuticals, Inc. ("Kolltan") in 2016, was primarily an income approach. The significant unobservable inputs used in the fair value measurement of the contingent consideration are estimates including probability of success, discount rates and amount of time until the conditions of the milestone payments are met. ​ During the three and six months ended June 30, 2022, the Company recorded a $6.3 million and $6.9 million gain on fair value remeasurement of contingent consideration, respectively, primarily due to the Company's decision to deprioritize the CDX-1140 program. During the three and six months ended June 30, 2021, the Company recorded a $0.3 million and $0.7 million loss on fair value remeasurement of contingent consideration, respectively, primarily due to changes in discount rates and the passage of time. The assumptions related to determining the fair value of contingent consideration include a significant amount of judgment, and any changes in the underlying estimates could have a material impact on the amount of contingent consideration adjustment recorded in any given period. ​ The Company did not have any transfers in or out of Level 3 assets or liabilities during the six months ended June 30, 2022.

X
- References No definition available. + Details
Name: | us-gaap_FairValueDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258 + Details
Name: | us-gaap_FairValueDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration